• Home
  • NEW DAY MEDICINE
  • 8 (82) 2025
  • 59 -8 (82) 2025 - Bobomuratov T.A., Avezova G.S. - HENOCH–SCHÖNLEIN PURPURA IN CHILDREN: CLINICAL FEATURES, TRIGGERING FACTORS, AND PRINCIPLES OF TREATMENT

59 -8 (82) 2025 - Bobomuratov T.A., Avezova G.S. - HENOCH–SCHÖNLEIN PURPURA IN CHILDREN: CLINICAL FEATURES, TRIGGERING FACTORS, AND PRINCIPLES OF TREATMENT

HENOCH–SCHÖNLEIN PURPURA IN CHILDREN: CLINICAL FEATURES, TRIGGERING FACTORS, AND PRINCIPLES OF TREATMENT

Bobomuratov T.A. - Tashkent State Medical University, Head of the Department of Propaedeutics of Childhood Diseases

Avezova G.S. - Tashkent State Medical University, Head of the Department of Propaedeutics of Childhood Diseases

Jaxonov A.X. - Alfraganus University

Resume

Objective: To analyze the clinical features, risk factors, laboratory and instrumental findings, and the effectiveness of conventional therapy in children with Henoch–Schönlein purpura (IgA vasculitis). Methods: A retrospective analysis was conducted of 416 pediatric patients diagnosed with Henoch–Schönlein purpura who were treated at Tashkent Medical Academy between 2012–2022, as well as children hospitalized at the City Children’s Clinical Hospital No. 3 during 2022–2024. Clinical forms, age and gender distribution, triggering factors, laboratory and instrumental indicators, and applied therapeutic approaches were evaluated. Results: The majority of cases occurred in children aged 7–14 years (71.7%), with a slight predominance of boys (51.4%). The main triggering factors were upper respiratory tract infections (50%), hypothermia (28%), and drug or food allergies (22%). The most common clinical forms were cutaneous and cutaneous-articular, while abdominal and nephritic forms were associated with more severe courses. Laboratory tests revealed coagulation abnormalities in 52% of patients and nephritic changes in 34.7%. Conventional combination therapy (glucocorticoids, antihistamines, anticoagulants, infusion therapy) achieved clinical remission within 10–14 days in 82.4% of cases, although recurrence rates showed a rising trend over time. Conclusion: Henoch–Schönlein purpura in children most frequently occurs at school age and has a polyetiological nature. Severe disease courses are mainly associated with nephritic and abdominal syndromes. Although conventional therapy is generally effective, the persistence of recurrences highlights the need for innovative treatment approaches. A comprehensive strategy with systematic monitoring of laboratory and instrumental parameters is essential to reduce complications and improve the quality of life in pediatric patients.

Keywords: Henoch–Schönlein purpura, IgA vasculitis, children, clinical features, risk factors, laboratory findings, therapeutic effectiveness, recurrence.

First page

330

Last page

338

For citation:Bobomuratov T.A., Avezova G.S., Jaxonov A.X. - HENOCH–SCHÖNLEIN PURPURA IN CHILDREN: CLINICAL FEATURES, TRIGGERING FACTORS, AND PRINCIPLES OF TREATMENT//New Day in Medicine 8(82)2025 330-338 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

  1. Иванов С.А., Петров В.Н., Смирнова Е.И. Клинические особенности и диагностика геморрагического васкулита у детей. Педиатрия. 2019; 98(4): 45–51.
  2. Кожевникова Е.В., Морозова Н.А., Николаева О.В. Патогенетические механизмы IgA-васкулита у детей. Вестник педиатрии. 2020; 5(2): 33–39.
  3. Calviño M.C., Llorca J., García-Porrúa C. Henoch–Schönlein purpura in children from northwest Spain: a 20-year epidemiologic and clinical study. Medicine. 2001; 80(5): 279–290.
  4. Chan H., Tang Y.M., Yuen Y.P. Clinical outcome of Henoch–Schönlein purpura in children: risk factors associated with renal involvement. Hong Kong Medical Journal. 2016; 22(6): 542–550.
  5. Davin J.C., Coppo R. Henoch–Schönlein purpura nephritis in children. Nature Reviews Nephrology. 2014; 10(10): 563–573.
  6. He X., Yu C., Zhao P. Risk factors for recurrence in children with Henoch–Schönlein purpura. Clinical Rheumatology. 2018; 37(9): 2543–2550.
  7. Ozen S., et al. Pediatric vasculitis: clinical features and management. Current Opinion in Rheumatology. 2018; 30(5): 514–522.
  8. Ozen S., Pistorio A., Iusan S.M., et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa and Takayasu arteritis. Annals of the Rheumatic Diseases. 2010; 69(5): 798–806.
  9. Pohl M., et al. Oxidative stress and vascular endothelial injury in Henoch–Schönlein purpura. Kidney International Reports. 2021; 6(4): 750–759.
  10. Ronkainen J., Koskimies O., Ala-Houhala M. Early prednisone therapy in Henoch–Schönlein purpura: a randomized clinical trial. Journal of Pediatrics. 2006; 149(2): 241–247.
  11. Saulsbury F.T. Clinical update: Henoch–Schönlein purpura. The Lancet. 2007; 369(9566): 976–978.
  12. Trapani S., Micheli A., Grisolia F. Henoch–Schönlein purpura in childhood: epidemiological and clinical analysis. Journal of Pediatrics. 2019; 204: 234–240.
  13. Weiss P.F., Klink A.J., Kimura Y. Clinical manifestations and treatment approaches in Henoch–Schönlein purpura. Journal of Rheumatology. 2021; 48(6): 820–828.
  14. Yang Y.H., Yu H.H., Chiang B.L. The diagnosis and classification of Henoch–Schönlein purpura: an updated review. Autoimmunity Reviews. 2014; 13(4–5): 355–358.
  15. Zhang Y., Liu H., Wang J. The role of infections and environmental factors in pediatric IgA vasculitis. Pediatric Nephrology. 2020; 35(3): 553–561.

    file

    download